|
Press Releases |
|
![](/images/company/nanobiotix.jpg) |
|
Wednesday, September 5, 2018 |
|
NANOBIOTIX half year results for the six months ended June 30, 2018 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended June 30 2018, from the consolidated financial statements at June 30, 2018 that have been reviewed by the supervisory board dated September 4, 2018. more info >> |
|
Friday, July 27, 2018 |
|
NANOBIOTIX signs a 40M EUR non-dilutive financing agreement with the European Investment Bank |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company launched a non-dilutive financial partnership with the European Investment Bank (EIB) to boost its research, development and innovation activities. more info >> |
|
Friday, June 22, 2018 |
|
NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma (STS). more info >> |
|
Wednesday, June 6, 2018 |
|
NANOBIOTIX' Management Statement on Recent Share Price Variation |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, communicates today regarding the recent evolution of its share price. more info >> |
|
Friday, May 4, 2018 |
|
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today that it is launching a research collaboration with Weill Cornell Medicine to begin nonclinical studies of NBTXR3's mechanism of action. more info >> |
|
Wednesday, April 18, 2018 |
|
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that preclinical data evaluating the activation of the cGAS-STING pathway by NBTXR3 has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago, Illinois (April 14-18, 2018). more info >> |
|
Wednesday, April 11, 2018 |
|
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate with The University of Texas MD Anderson Cancer Center, Houston TX, to work on NBTXR3, Nanobiotix's lead product. more info >> |
|
Friday, March 30, 2018 |
|
Nanobiotix 2017 Annual Results |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2017. more info >> |
|
Monday, January 22, 2018 |
|
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of intermediate data on the safety and feasibility in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and liver metastasis from other tumors. more info >> |
|
Thursday, January 11, 2018 |
|
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors and activation by radiotherapy. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Best BLUETTI Prime Day Deals on Portable Power Stations and Solar Generators
Jul 16, 2024 22:00 HKT/SGT
|
|
|
Lexaria Preparing For Strategic Growth
Jul 16, 2024 21:20 HKT/SGT
|
|
|
'Alamein Festival' Launches Exciting Second Edition for 2024
Jul 16, 2024 21:00 HKT/SGT
|
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating
Jul 16, 2024 21:00: JST
|
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating
Jul 16, 2024 20:00 HKT/SGT
|
|
|
How Artificial Intelligence Can Help Give Your Business a Boost
Jul 16, 2024 19:30 HKT/SGT
|
|
|
U.S. Polo Assn. Proudly Partners with the 2024 Outsourcing Inc. Royal Charity Polo Cup
Jul 16, 2024 19:00 HKT/SGT
|
|
|
Neste and Mitsubishi Corporation agree on strategic partnership to develop supply chains for renewable chemicals and plastics
Jul 16, 2024 18:36 JST
|
|
|
NEC technology reliably measures sea levels from a greater distance
Jul 16, 2024 17:45 JST
|
|
|
全球发展数字经济直播访谈会正式举办 外方来华参会高级别代表走进东方甄选直播间
Jul 16, 2024 15:08 HKT/SGT
|
|
|
巨星傳奇(6683.HK)解禁後首個交易日 收盤報10.4港元 升幅達2.97%
Jul 16, 2024 15:04 HKT/SGT
|
|
|
巨星传奇(6683.HK)解禁后首个交易日: 收盘报10.4港元 升幅达2.97%
Jul 16, 2024 14:58 HKT/SGT
|
|
|
全球發展數字經濟直播訪談會正式舉辦 外方來華參會高級別代表走進東方甄選直播間
Jul 16, 2024 14:25 HKT/SGT
|
|
|
Fujitsu and Cohere launch strategic partnership and joint development to provide generative AI for enterprises
Jul 16, 2024 15:13 JST
|
|
|
Komisi Penerbangan Malaysia Memilih TransNusa Sebagai Salah Satu Dari Dua Maskapai Asing Untuk Meluncurkan Penerbangan Dari Bandara Subang
Jul 16, 2024 14:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|